Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Mann

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Current Therapeutic Research, Clinical and Experimental|September 6, 2021
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC StudyMario Ouwens, Annie Darilay, Yiduo Zhang, et al.
Age and Ageing|June 26, 2020
Driving in Parkinson's disease: a retrospective study of driving and mobility assessmentsKatherine Lloyd, Daisy Gaunt, Victoria Haunton, et al.
Journal of Transport & Health|August 21, 2025
The effectiveness of behavioural interventions on young, novice drivers' motor vehicle crash risk: A systematic reviewJessica Hafetz, Jackson Felkins, Ayden Allston, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
Clinical Drug Investigation|December 17, 2017
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKIHelen Mann, Frank Andersohn, Carolyn Bodnar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFICJarushka Naidoo, Scott Antonia, Yi-Long Wu, et al.
Breast Cancer Research and Treatment|September 23, 2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancerStephen Johnston, Mark Basik, Roberto Hegg, et al.
Frontiers in Immunology|November 21, 2022
Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumabAgnish Dey, Matthew Austin, Harriet M Kluger, et al.
Journal of Clinical Pharmacology|March 16, 2019
Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung CancerEmiliano Calvo, Jong-Seok Lee, Sang-We Kim, et al.
Future Oncology (London, England)|May 7, 2025
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN studyMustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Current Therapeutic Research, Clinical and Experimental|September 6, 2021
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC StudyMario Ouwens, Annie Darilay, Yiduo Zhang, et al.
Age and Ageing|June 26, 2020
Driving in Parkinson's disease: a retrospective study of driving and mobility assessmentsKatherine Lloyd, Daisy Gaunt, Victoria Haunton, et al.
Journal of Transport & Health|August 21, 2025
The effectiveness of behavioural interventions on young, novice drivers' motor vehicle crash risk: A systematic reviewJessica Hafetz, Jackson Felkins, Ayden Allston, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
Clinical Drug Investigation|December 17, 2017
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKIHelen Mann, Frank Andersohn, Carolyn Bodnar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFICJarushka Naidoo, Scott Antonia, Yi-Long Wu, et al.
Breast Cancer Research and Treatment|September 23, 2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancerStephen Johnston, Mark Basik, Roberto Hegg, et al.
Frontiers in Immunology|November 21, 2022
Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumabAgnish Dey, Matthew Austin, Harriet M Kluger, et al.
Journal of Clinical Pharmacology|March 16, 2019
Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung CancerEmiliano Calvo, Jong-Seok Lee, Sang-We Kim, et al.
Future Oncology (London, England)|May 7, 2025
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN studyMustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, et al.
Pageof 6